Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Ptc Therapeutics (PTCT) EPS (Basic) (2016 - 2025)

Ptc Therapeutics (PTCT) has 14 years of EPS (Basic) data on record, last reported at $0.2 in Q3 2025.

  • For Q3 2025, EPS (Basic) rose 114.39% year-over-year to $0.2; the TTM value through Sep 2025 reached $9.05, up 252.1%, while the annual FY2025 figure was $8.58, 281.4% up from the prior year.
  • EPS (Basic) reached $0.2 in Q3 2025 per PTCT's latest filing, down from $11.09 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $11.09 in Q1 2025 and bottomed at -$2.66 in Q2 2023.
  • Average EPS (Basic) over 5 years is -$0.95, with a median of -$1.77 recorded in 2022.
  • Peak YoY movement for EPS (Basic): plummeted 87.96% in 2021, then surged 1024.17% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$2.03 in 2021, then dropped by 16.26% to -$2.36 in 2022, then rose by 12.29% to -$2.07 in 2023, then soared by 58.94% to -$0.85 in 2024, then skyrocketed by 123.53% to $0.2 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were $0.2 in Q3 2025, $11.09 in Q1 2025, and -$0.85 in Q4 2024.